Nectero EAST System Evaluated for Treating Small- to Medium-Sized AAA

May 20, 2026—Nectero Therapeutics announced the release of 2-year outcomes from the company’s first-in-human (FIH) trial of the investigational Nectero endovascular aneurysm stabilization treatment (EAST) system.

According to the company, its Nectero EAST therapy is intended to treat patients with small- to medium-sized aneurysms earlier in the abdominal aortic aneurysm (AAA) disease process, with the potential to delay or avoid higher risk endograft or open repair procedures. The investigational drug contains the active pharmaceutical ingredient pentagalloylglucose (PGG). It is administered as a single treatment delivered locally into the aneurysmal wall using a dual-balloon delivery catheter, the company noted.

Andrew Holden, MD, presented the Nectero EAST FIH AAA trial data during a session on AAA disease management at the CX 2026, the 48th Charing Cross Symposium held April 21-23 in London, United Kingdom.

As summarized in the Nectero press release, the FIH study enrolled 46 patients (average age, 70 years; male, 89%; average body mass index, 27 kg/m²) with aneurysms of a median maximum diameter of 4.3 cm. The average procedure time was < 45 minutes, with 100% technical success in delivering the therapy. There were no major adverse events through 30 days, and no treatment-related adverse events were reported after 30 days.



The company reported that, at 2-year follow-up, the median aneurysm diameter growth was 1.00 mm per year, representing a significant reduction in the expected AAA growth rate, with approximately 90% of the aneurysms growing less than expected compared to what has been historically documented and published. Additionally, the AAA proximal neck diameters remained stable with no dilatation in the 1-year preliminary analysis, stated Nectero.



“Through 2-year follow-up in this FIH trial, it’s been shown that a single, local dose of PGG in patients with small- to medium-sized AAAs demonstrates an acceptable safety profile with a profound impact on reducing AAA growth,” commented Dr. Holden in the company’s press release. “Additionally, we’ve seen a positive, early clinical signal toward proximal neck stabilization.”



A full 2-year analysis on AAA proximal neck diameters will be released during a late-breaking session at VAM 2026, the Vascular Annual Meeting held June 10-13 in Boston, Massachusetts. The 3-year follow-up from the FIH trial will be completed by the end of 2026, advised Nectero.